HIV

On November 12th, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending marketing authorisation for dolutegravir 5mg dispersible tablets for young children living with HIV. This decision was based, in part, on data from the ODYSSEY trial.

These small tablets can now be used in combination with other medicines for treating children living with HIV who are aged at least four weeks and weigh at least 3kg.

This workshop will be focused on the importance of research in paediatric, adolescent, and maternal HIV infections. This type of research is critical to achieving an AIDS-free generation. Unfortunately, children are substantially less likely than adults to be diagnosed, engaged in care, and to access life-saving ART.

The HIV Paediatrics Workshop is the only meeting entirely devoted to research in the prevention and treatment of HIV infections in infants,

The Central and Eastern European Meeting on Viral Hepatitis and HIV is an independent program, initiated in 2014 and developed by regional and international key opinion leaders for the medical and scientific community in Eastern and Central European countries.

The target audience of this meeting consists of healthcare professionals involved in daily care for HCV patients such as infectious disease doctors, gastroenterologists, hepatologists and others.

The sixth edition of the Central and Eastern European Meeting on Viral Hepatitis and HIV will be held as a virtual conference.

Penta has been invited to run a one-day session at the Republican Hospital of Infectious Diseases, St Petersburg conference on ‘Actual problems of HIV Infection: Mother and Child’ on Tuesday 15^th September. The Penta session What’s new for children and women living with HIV: interactive clinical day with Penta will look at new data on ART in pregnancy and newborns, resistance and recommendations for 1st,

Authors: Bollen P, Freriksen J, Konopnicki D, Weizsäcker K , et al; on behalf of the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women Network

Published in: Clin infect Dis. 2020;26.ciaa006

Background Pharmacokinetic and efficacy data on dolutegravir in pregnant women living with human immunodeficiency virus (HIV) are still limited but needed to support its use as one of the preferred antiretroviral agents.

Last Patient Last Visit (LPLV) completed for the Penta 17 Strategy for Maintenance of HIV suppression with integrase inhibitor + darunavir/ritonavir in children (SMILE) trial.

The Penta sponsored trial, SMILE, has completed its last patient last visit. This exciting news comes to us following the closure of patient enrolment for SMILE last year, where all participants recruited were followed up for a minimum of 48 weeks until the last participant enrolled reached 48 weeks of follow-up on 11 August 2020.

Results from from the ongoing P1093 and ODYSSEY (PENTA20) studies, published in The Lancet HIV journal, show that children over 20kg in weight can safely take adult doses (50mg) of the anti-HIV drug dolutegravir. With over half of children living with HIV globally weighing at over 20kg, this expands treatment options and simplifies treatment for children.

These data have already had impact!

We are proud to announce that the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) was awarded a grant from the ViiV Global HIV and COVID-19 Emergency Fund to conduct research on the direct and indirect impact of COVID-19 on children and adolescents living with HIV across Europe and South Africa.

Europe has been severely affected by COVID-19, and South Africa has a high burden of paediatric HIV and has been hit hardest by the COVID-19 epidemic in sub-Saharan Africa to date. 

The 23^rd International AIDS Conference take virtually place from today to July 10^th. Attendants have the possibility to engage with the latest HIV science, advocacy and knowledge and also to hear about recent data on COVID-19 and HIV during the Virtual COVID-19 Conference that will be held on July 10^th-11^th.

EPIICAL Project will contribute to the conference presenting data related to early-treated HIV-infected children.

Data from the ongoing P1093 and ODYSSEY (PENTA20) studies have led to the successful approval of ViiV Healthcare’s submission to the U.S. Food and Drug Administration (FDA) of the adult formulation for children weighing ≥20kg and dolutegravir (DTG) dispersible tablets for children of 4 weeks of age and older.

The approval of adult 50mg DTG for use for children weighing ≥20kg allows for immediate access to adult DTG formulation procured and available in many countries for the majority of children living with HIV.

Join the 6th Workshop on Children and Adolescents HIV-exposed and Uninfected (HEU) at 3pm (CEST) on 1st July 2020.

The workshop is part of the pre-conference programme of the International AIDS virtual conference 2020. This is a unique opportunity to focus on the paediatric population and explore health issues and developmental disparities experienced by these patients.
Among speakers, our friend and collaborator Martina Penazzato, will provide an update on the emerging research and policies for HEU children.

Today marks the International Day of Action for Women’s Health. On this occasion, European AIDS Clinical Society (EACS) interviewed our friend and collaborator Dr. Karoline Aebi-Popp. She is the chair of the EACS programme promoting the welfare of HIV-positive women in Europe called WAWE (Women Against Viruses in Europe).

“HIV testing is the key to prevent vertical transmission of HIV to the baby.

The annual Conference on Retroviruses and Opportunistic Infections (CROI) will be held from March 8 to 11 in Boston, Massachusetts.

CROI brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS and related infectious diseases.

Details of the presentations related to projects and studies in which Penta is involved taking place at the conference are shown below.

The 10th international workshop on HIV and women is taking place in Boston, MA, USA on March 6-7. This is an outstanding opportunity for health care providers, researchers, government, industry and community to discuss, debate, and further their knowledge on the issues related to HIV and women. 

The format of the meeting enables attendees to learn from experts in the field of HIV and related health,

The 10th International Workshop on HIV & Women is in Boston on 6 – 7 March 2020, just prior to CROI.

This is an outstanding opportunity for health care providers, researchers, government, industry and community representatives to discuss, debate, and increase their knowledge on HIV and its burden on women.

The format of the meeting enables attendees to learn from experts in the field of HIV and related health,